UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): April 30, 2013
Commission File Number: 000-54014
VistaGen Therapeutics, Inc.
(Exact name of small business issuer as specified in its charter)
Nevada
(State or other jurisdiction of incorporation or organization)
20-5093315
(IRS Employer Identification No.)
384 Oyster Point Blvd, No. 8, South San Francisco, California 94080
(Address of principal executive offices)
650-244-9990
(Registrant's Telephone number)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 1.01 Entry into a Material Definitive Agreement.
On April 30, 2013, VistaGen Therapeutics, Inc. (the “Company”) and Bergamo Acquisition Corp. PTE LTD (“Bergamo”) entered into an amendment (the “Amendment”) to the Securities Purchase Agreement (the “Agreement”), dated April 8, 2013, and assigned to Bergamo pursuant to the terms of an Assignment and Assumption Agreement, dated April 12, 2013. The Amendment amends the scheduled investment dates, so that the first closing shall occur on or before May 15, 2013 and the final closing shall occur on or before September 30, 2013, as more particularly set forth below:
|
Investment Date
|
Total Amount of Investment
|
Total No. of Shares
|
||
|
On or before May 15, 2013
|
$1,000,000
|
2,000,000
|
||
|
On or before May 31, 2013
|
$2,000,000
|
4,000,000
|
||
|
On or before June 30, 2013
|
$8,250,000
|
16,500,000
|
||
|
On or before July 30, 2013
|
$8,250,000
|
16,500,000
|
||
|
On or before August 31, 2013
|
$8,250,000
|
16,500,000
|
||
|
On or before September 30, 2013
|
$8,250,000
|
16,500,000
|
The foregoing description of the Amendment does not purport to be complete, and is qualified in its entirety by reference to the text of the Amendment, which is attached hereto as Exhibit 10.1 and incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
| Exhibit Number | Description | |
| 10.1 | Amendment No. 1 to the Securities Purchase Agreement |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
VistaGen Therapeutics, Inc.
|
|
Date:
|
May 1, 2013
|
|
|
By:
|
/s/ Shawn K. Singh
|
|
|
Name: Shawn K. Singh, JD
|
||
|
Title: Chief Executive Officer
|
||
Exhibit 10.1
AMENDMENT NO. 1 TO SECURITIES PURCHASE AGREEMENT
This Amendment No. 1 to Securities Purchase Agreement (“Amendment”) is entered into as of April 30, 2013, by and between VistaGen Therapeutics, Inc., a Nevada corporation (the “Company”), and Bergamo Acquisition Corp. PTE LTD, a company organized and existing under the laws of Singapore (“Purchaser”). Unless otherwise specified herein, all capitalized terms set forth in this Amendment shall have the meanings as set forth in the Agreement (as defined below).
RECITALS
WHEREAS, Purchaser assumed all obligations under that certain Securities Purchase Agreement, dated April 8, 2013 (the “Agreement”), by and between the Company and an affiliate of Purchaser, pursuant to the terms of an Assignment and Assumption Agreement, dated as of April 12, 2013;
WHEREAS, subject to the terms and conditions set forth in the Agreement, Purchaser agreed to purchase from the Company an aggregate of 72 million restricted shares of Common Stock of the Company (“Shares”) for aggregate consideration of U.S. $36.0 million; and
WHEREAS, the Company and Purchaser desire to amend the Agreement as more particularly set forth in this Amendment.
AGREEMENT
For good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the undersigned parties agree as follows:
1. Section 2.1 of the Agreement is hereby amended and replaced in its entirety with the following:
Section 2.1 Closing; Investment Dates
Upon the terms and subject to the conditions set forth herein, the Company agrees to sell, and the Purchaser agrees to purchase, Seventy Two Million (72,000,000) Shares of Common Stock of the Company for Thirty Six Million Dollars ($36,000,000), or $0.50 per share, in a series of tranches (each, a “Closing” and the date of each such Closing an “Investment Date”) in accordance with the schedule set forth below:
|
Investment Date
|
Total Amount of Investment
|
Total No. of Shares
|
||
|
On or before May 15, 2013
|
$1,000,000
|
2,000,000
|
||
|
On or before May 31, 2013
|
$2,000,000
|
4,000,000
|
||
|
On or before June 30, 2013
|
$8,250,000
|
16,500,000
|
||
|
On or before July 30, 2013
|
$8,250,000
|
16,500,000
|
||
|
On or before August 31, 2013
|
$8,250,000
|
16,500,000
|
||
|
On or before September 30, 2013
|
$8,250,000
|
16,500,000
|
On each Investment Date, the Company and Purchaser shall deliver the items set forth in Section 2.3 deliverable at the Closing; provided, however, the opinion of Company Counsel required by Section 2.3(a)(vii) shall only be required to be delivered as a condition to the Closing of the final tranche of $8,250,000. Upon satisfaction of the covenants and conditions set forth in Section 2.3, each Closing shall occur at the offices of Company Counsel or such other location as the parties shall mutually agree.
The Company and Purchaser represent and warrant to each other as follows:
(a) The execution, delivery and performance of this Amendment are within the power and authority of the Company and Purchaser and are not in contravention of law, Articles of Incorporation, By-laws or the terms of any other documents, agreements or undertakings to which the Company or Purchaser is a party or by which the Company or Purchaser is bound. No approval of any person, corporation, governmental body or other entity not provided herewith is a prerequisite to the execution, delivery and performance by the Company or Purchaser of this Amendment, to ensure the validity or enforceability thereof.
(d) When executed on behalf of the Company and Purchaser, this Amendment will constitute the legally binding obligations of the Company and Purchaser, enforceable in accordance with their terms, subject to the effect of applicable bankruptcy, insolvency, reorganization, moratorium and other similar laws now existing or hereafter enacted relating to or affecting the enforcement of creditors’ rights generally, and the enforceability may be subject to limitations based on general principles of equity (regardless of whether such enforceability is considered a proceeding in equity or at law).
3. The provisions of the Agreement, as modified in this Amendment, shall remain in full force and effect in accordance with their terms and are hereby ratified and confirmed. In the event of any conflict between the terms and conditions of this Amendment and the terms and conditions set forth in the Agreement, the terms and conditions set forth herein shall control. This Amendment shall be governed by the laws of the State of Delaware without regard to the conflict of laws provisions thereof.
IN WITNESS WHEREOF, this Amendment is executed as of the day and year first written above.
|
VISTAGEN THERAPEUTICS, INC.
|
|
|
By: /s/ Shawn Singh
Name: Shawn Singh
Title: Chief Executive Officer
|
|
|
BERGAMO ACQUISITION CORP. PTE LTD
|
|
|
By: /s/ Hillard Herzog
Name: Hillard Herzog
Title: President
|